Financial Snapshot
What does STERIS plc’s latest financial snapshot show?
Strong. The biggest strength is cash generation, while the main concern is tariff pressure and capital spending.
For Fiscal 2026, STERIS plc’s snapshot blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. That makes the verdict useful for a quick investor read, especially alongside company context in STERIS plc (STE): History, Ownership, Mission, How It Works & Makes Money.
In Fiscal 2026, $59B annual revenue and $134B net cash provided by operations anchor the picture, and the 25% free cash flow growth is the first metric worth deeper analysis.
Recurring quality
Is STERIS plc's revenue growth producing quality earnings?
Strong. The clearest confirmation is that 9% fiscal 2026 revenue growth and 7% constant currency organic growth were supported by a business mix built on installed equipment, proprietary consumables, and service contracts, while earnings and EPS also rose.
Growth quality looks stronger when revenue comes from repeat demand, not one-time sales. Investors compare revenue durability with operating income, net income, and EPS across comparable annual periods because steady top-line growth should also show up in profits, and the STERIS plc (STE): History, Ownership, Mission, How It Works & Makes Money model helps explain that link.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $59B fiscal 2026; 9% growth; 7% constant currency organic growth | Previous comparable revenue not provided | Organic growth; repeatable demand appears supported by consumables and service | Repeat revenue is usually more durable than one-time equipment sales |
| Operating Income | Fiscal 2026 direction not separately provided | Previous comparable value not provided | Could not verify operating leverage from the supplied annual data | Harder to judge margin expansion without the operating income line |
| Net Income | $7823M from continuing operations fiscal 2026; adjusted net income $10B | Previous comparable value not provided | Reported and adjusted results both increased, but adjusted items are not separated here | Final earnings support the revenue trend, though quality is best judged on reported results |
| Diluted EPS | $1017 adjusted EPS fiscal 2026; EPS growth 10% | Previous comparable diluted EPS not provided | Per-share growth is positive; share-count effect not provided | Shareholders saw earnings growth at the per-share level |
How durable is STERIS plc's revenue?
Durable. The strongest signal is the installed-base model, where equipment sales support recurring consumables and service revenue. The biggest visibility limit is mix concentration, with Healthcare at about 70% of revenue.
- Demand Quality: Recurring consumables and service contracts tied to installed equipment improve visibility and reduce reliance on one-off sales.
- Pricing and Volume: The price-volume split was not provided; constant currency organic growth of 7% suggests underlying operating demand, but the mix detail is unavailable.
- Diversification: Segment mix is concentrated in Healthcare at about 70%, with AST at about 19% and Life Sciences at about 11%.
That mix matters because recurring revenue usually supports steadier profitability and cash conversion.
Margins and cash
Do STERIS plc profits turn into strong free cash flow?
Yes. STERIS plc’s gross margin slipped to 44% in Fiscal 2026 under tariff pressure, but operating cash flow and free cash flow still strengthened, which supports the reported earnings. The cash results look stronger than the margin squeeze suggests.
Gross margin shows product economics, operating margin shows how well the business scales, and net margin shows what is left after interest and taxes. In Fiscal 2026, net income from continuing operations was $7823M, while cash flow mattered more for quality: operations produced $134B and free cash flow was $9829M. For strategy context, see Mission Statement, Vision, & Core Values (2026) of STERIS plc (STE).
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | 44% (Fiscal 2026) | 44.8% (Fiscal 2025, implied by 80 basis point tariff compression) | $46M–$55M pre-tax tariff impact; 80 basis point compression from tariffs | Product economics softened, but the core model still held up. |
| Operating Margin | 233% (Fiscal 2026) | Unavailable from supplied data | Verified operating leverage data not provided | Scale effects cannot be measured cleanly from the supplied figures. |
| Net Margin | Unavailable from supplied data | Unavailable from supplied data | Adjusted Effective Tax Rate (Fiscal 2026): 244%, up 130 basis points from prior year | Final profitability is harder to assess without a revenue base and full income-statement detail. |
| Operating Cash Flow | $134B (Fiscal 2026) | Comparable FMP 2026-03-31 operating cash flow growth: 1247% | Working-capital details not supplied; cash growth outpaced reported earnings signals | Reported earnings appear to convert into cash, which improves earnings quality. |
| Free Cash Flow | $9829M (Fiscal 2026) | Comparable FMP 2026-03-31 free cash flow growth: 2291% | Annual capital expenditures: $369M | After investment, STERIS plc still had substantial cash left for reinvestment or financing. |
What most affects STERIS plc cash conversion?
Tariff-driven gross margin pressure is the clearest verified drag, but strong operating cash flow and limited capital spending show that cash conversion still held up well.
- Main Driver: Tariff pressure caused 80 basis point gross margin compression; that looks partly structural unless pricing or sourcing improves.
- Evidence Gap: The supplied data does not show working-capital components or a full revenue bridge.
- Metric to Monitor: Gross margin and operating cash flow in the next period.
Debt Capacity
Can STERIS comfortably handle its debt?
STERIS plc is Mixed. The main protection is cash generation, with Net Cash Provided by Operations (Fiscal 2026): $134B, but the main concern is leverage, including Total Debt: $19B and a Gross Debt to EBITDA Ratio: 12x.
Cash alone does not tell the whole story. A real balance-sheet check also needs working capital, asset quality, debt service, solvency, liquidity, and refinancing access. STERIS plc’s operating cash flow helps, but detailed maturity, rate, covenant, and short-term working-capital terms are not supplied here.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Net Cash Provided by Operations (Fiscal 2026): $134B; detailed current assets, current liabilities, receivables, inventory, and liquidity ratios not supplied. | Mixed | Operating cash flow supports near-term obligations, but the missing working-capital detail limits a full liquidity check. |
| Total and Net Debt | Total Debt: $19B; enterprise value data also lists Minus Cash And Cash Equivalents: $43960M and Add Total Debt: $209B, but that is not a balance-sheet substitute. | Mixed | Debt is meaningful enough to limit flexibility, even with cash on hand and strong operating cash generation. |
| Debt Service and Refinancing | Gross Debt to EBITDA Ratio: 12x; interest expense, maturities, covenant terms, and refinancing access are not supplied. | Mixed | Cash flow suggests debt service is manageable, but refinancing risk cannot be ruled out without maturity and rate detail. |
| Asset Quality | Goodwill, intangibles, receivables, inventory, and impairment data are not supplied here. | Mixed | Asset quality cannot be fully tested, so investors should watch for hidden impairment or collection risk. |
| Liabilities and Equity | Latest verified total liabilities and shareholders' equity are not supplied; see also Mission Statement, Vision, & Core Values (2026) of STERIS plc (STE) for strategic context. | Mixed | The capital base cannot be fully measured here, so leverage coverage should be judged conservatively. |
Which balance-sheet risk matters most for STERIS plc?
Leverage is the main risk. The 12x gross debt to EBITDA reading is the clearest warning because it suggests limited room if cash flow weakens or refinancing gets more expensive.
- Current Exposure: Total Debt: $19B and Gross Debt to EBITDA Ratio: 12x.
- Protection: Net Cash Provided by Operations (Fiscal 2026): $134B provides cash-flow support.
- Warning Signal: Watch whether debt stays high while refinancing terms, interest costs, or operating cash flow weaken.
Capital Efficiency
Does STERIS fund growth without straining returns?
STERIS looks Strong on capital efficiency, and internal cash generation appears sufficient for reinvestment needs based on $982.9M of free cash flow and $1.34B of net cash provided by operations in Fiscal 2026.
Return quality still needs to be read alongside leverage, asset intensity, capital expenditure, working capital, and any external funding needs. STERIS spent $369M on annual capital expenditures and guided to about $375M for Fiscal 2027, including a new manufacturing plant in Mentor, Ohio. For investor context, see Exploring STERIS plc (STE) Investor Profile: Who's Buying and Why?
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable | Cannot be verified from the supplied data set. | Investors should watch whether operating performance keeps supporting capital deployment. |
| ROE and ROA | Unavailable | Leverage and asset-efficiency effects cannot be separated from the supplied data. | Shareholder return quality cannot be judged here without the missing ratios. |
| Maintenance and Growth Investment | $369M annual capex; about $375M guided for Fiscal 2027, including a new plant in Mentor, Ohio. | Capex appears to support both ongoing operations and expansion, but the split is not fully disclosed. | Capital spending looks meaningful, but the company is still funding growth from strong internal cash flow. |
| Internal Funding Capacity | $982.9M free cash flow; $1.34B net cash provided by operations; $225M total share buybacks; new $10B share repurchase program; quarterly dividend of $0.63 per share; annualized dividend of $2.52; total dividend growth: 20th consecutive year | Investment and shareholder returns appear internally funded, with no need to assume outside capital from the supplied figures. | That supports flexibility for buybacks, dividends, and plant spending, while also leaving room for reinvestment. |
Are STERIS's returns on capital sustainable?
Yes, as long as operating cash stays strong; the main durability support is internal cash generation, while heavier plant spending or weaker free cash flow would pressure returns and funding flexibility.
- Operating Source: Strong operating cash flow and free cash flow support reinvestment, buybacks, and dividends.
- Funding Requirement: The largest verified capital need is about $375M of Fiscal 2027 capex, including the Mentor plant.
- Durability Test: Returns weaken if free cash flow falls below reinvestment and shareholder payout needs, especially with higher capex.
Financial Resilience
How resilient is STERIS plc, and which warning signs matter most?
Resilience is Mixed. The main buffer is backlog and recurring demand, including $3,921M in Healthcare segment total backlog and $4,907M in total capital equipment backlog. The most important verified warning sign is tariff cost pressure, with a $46M–$55M Fiscal 2026 pre-tax tariff impact expected.
STERIS can absorb some stress because demand visibility is still supported and no material cybersecurity incidents were reported during the twelve-month period preceding June 09, 2026. Still, resilience is not unlimited: tariff costs, sterilization regulation risk, and supply chain constraints could all squeeze cash flow, so the link STERIS plc (STE): History, Ownership, Mission, How It Works & Makes Money helps readers connect this pressure to the business model.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Tariffs could reduce operating leverage and earnings, with a $45M–$55M annual cost pressure and a $46M–$55M Fiscal 2026 pre-tax tariff impact that can tighten debt capacity and cash generation. | Fiscal 2026 EBIT Margin Expansion of 10 basis points shows partial resilience, which suggests pricing, mix, or cost control is offsetting some pressure. | Watch for margin compression, slower earnings growth, or weaker cash flow that would show the tariff drag is broadening. |
| Working-Capital or Investment Pressure | Advanced sterilizers can face supply chain constraints, which may tie up inventory, delay deliveries, and absorb cash needed for capex and other investment. | Demand visibility is supported by $3,921M Healthcare segment total backlog and $4,907M total capital equipment backlog. | Monitor backlog conversion, operating cash flow, and any inventory build or slower shipment timing. |
| Interest or Refinancing Pressure | If margins and cash flow weaken, fixed obligations become harder to service and refinancing flexibility can narrow. | Backlog support and ongoing operating resilience help protect internal funding, while no material cybersecurity incidents were reported in the latest twelve-month period. | Watch debt levels, interest expense, and liquidity trends for signs that financing pressure is rising. |
What financial warning signs should investors monitor at STERIS plc?
The strongest signals are tariff-driven margin compression, weaker backlog conversion, and any slowdown in operating cash flow. Tariff pressure is a confirmed near-term risk; supply chain strain and refinancing pressure are more future risks unless they start showing up in results.
Tariff Cost Pressure Hits Margins First
STERIS expects a $46M–$55M Fiscal 2026 pre-tax tariff impact, so margins are the clearest stress point. The partial offset is 10 basis points of EBIT Margin Expansion, but investors should track whether earnings and cash flow still hold up.
Sterilization Regulation Risk
EPA public hearings on proposed revisions to EtO rules matter because STERIS monitors potential impacts across more than 50 global contract sterilization facilities. The key metric is whether regulatory changes force costly compliance work, operating limits, or service disruption.
Supply Chain Delays in Capital Equipment
Supply chain constraints can slow advanced sterilizer shipments and delay cash collection. The mitigating factor is strong backlog, including $3,921M in Healthcare segment total backlog and $4,907M in total capital equipment backlog, so delivery timing is the next metric to watch.
Investor Scorecard
What does STERIS's financial health mean for investors?
STERIS looks Strong overall, led by revenue growth and cash generation. The weakest point is mixed capital efficiency, while the most important investment condition is whether free cash flow stays solid as leverage and cost pressure remain controlled.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | Annual Revenue (Fiscal 2026): $59B, Revenue Growth: 9%, Constant Currency Organic Growth: 7%, and EPS Growth: 10% show durable demand and real per-share conversion. |
| Profitability and Cash | Strong | Gross Margin (Fiscal 2026): 44%, EBIT Margin (Fiscal 2026): 233%, Net Cash Provided by Operations (Fiscal 2026): $134B, and Free Cash Flow: $9829M point to strong cash generation. |
| Balance Sheet and Liquidity | Strong | Total Debt: $19B and Gross Debt to EBITDA Ratio: 12x are manageable, but missing maturity and covenant detail limits certainty on refinancing risk. |
| Capital Efficiency | Mixed | Capex, dividends, buybacks, and plant investment are still internally supported, but rising spending lowers near-term flexibility and can pressure returns if growth slows. |
| Financial Resilience | Mixed | Tariffs, EtO rules, and supply constraints create real operating pressure, so resilience depends on keeping margins and cash flow stable through disruption. |
- What Supports the Thesis: Strong growth, high cash generation, and controlled leverage support the view that STERIS can fund operations and investment internally. Mission Statement, Vision, & Core Values (2026) of STERIS plc (STE)
- What Challenges the Thesis: Rising spending, tariff cost pressure, and regulatory risk can weaken cash conversion and limit margin expansion.
- What to Monitor: Fiscal 2027 Free Cash Flow Guidance: approx $850M; tariff cost pressure $45M–$55M; Gross Debt to EBITDA Ratio: 12x.
For forecasts, scenarios, and valuation work, the key question is whether STERIS can keep converting growth into cash while managing leverage and cost pressure.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
What does STERIS's 233% EBIT Margin mean?
It means STERIS kept a strong operating profit base in fiscal 2026 after operating costs, before interest and taxes The margin expanded by 10 basis points despite 80 basis point compression from tariffs, which supports the financial health case
How does STERIS fund capex and dividends?
STERIS appears to fund reinvestment and shareholder returns mainly from internal cash generation Fiscal 2026 Net Cash Provided by Operations was $134B, Free Cash Flow was $9829M, and Annual Capital Expenditures were $369M
Is STERIS's 12x debt ratio concerning?
Gross Debt to EBITDA Ratio: 12x does not look high when paired with strong operating cash flow Investors should still review maturity schedules, interest rates, and covenant terms because those details are not supplied here
What risks could pressure free cash flow next?
The main free cash flow watch items are tariff cost pressure $45M–$55M annually, higher capital spending, working capital needs, and EtO regulatory changes Fiscal 2027 Free Cash Flow Guidance is approx $850M
Does STERIS have enough liquidity flexibility?
Liquidity is supported by fiscal 2026 operating cash flow and manageable leverage However, the supplied data does not include full working-capital detail, debt maturity schedules, borrowing capacity, or covenant terms, so investors should not overstate liquidity comfort